Kentucky 2024 Regular Session

Kentucky House Bill HB220

Introduced
1/10/24  
Refer
1/10/24  
Refer
1/24/24  
Report Pass
1/31/24  
Engrossed
2/5/24  
Refer
2/5/24  
Refer
2/22/24  
Report Pass
2/27/24  
Enrolled
3/8/24  
Enrolled
3/8/24  
Chaptered
3/14/24  

Caption

AN ACT relating to step therapy protocols.

Impact

The proposed legislation would have a significant impact on how step therapy is implemented across state laws, giving patients greater protection against potentially harmful delays in obtaining necessary prescriptions. It emphasizes patient-centered care by allowing healthcare providers to advocate for their patients' needs more effectively. The bill also aims to promote transparency in the protocols used for determining medication coverage, which could ultimately lead to lower healthcare costs and improved patient outcomes.

Summary

House Bill 220 aims to regulate step therapy protocols used by insurers, health plans, and pharmacy benefit managers. Specifically, it establishes guidelines that require these entities to provide clear processes for step therapy exception requests, ensuring that patients have the opportunity to access medically necessary medications without undue delay. By mandating that insurers respond to exception requests within a stipulated time frame and outlining the conditions under which exceptions should be granted, the bill seeks to enhance patient access to essential treatments.

Sentiment

The sentiment surrounding HB 220 has been predominantly positive, with support from various healthcare advocacy groups and patient rights organizations. Advocates argue that the bill is a necessary step towards fostering a more equitable healthcare system where patients are not forced to cycle through less effective treatments before accessing the medication that best suits their needs. However, there are concerns among some insurers about the potential administrative burdens that may arise from the new requirements.

Contention

While many legislators support the bill, some stakeholders express apprehension regarding its implications for insurance companies and the possibility of increased costs. The debate has highlighted the tension between ensuring patient access to timely care and the operational realities faced by insurers as they adjust to more stringent regulatory requirements. This tension underscores the ongoing discussion about how best to balance patient advocacy with the sustainability of healthcare financing.

Companion Bills

No companion bills found.

Similar Bills

MS SB2675

Pharmacists; authorize to test for and administer treatment for minor, nonchronic health conditions.

MS HB791

Pharmacists; authorize to test for and administer treatment for minor, nonchronic health conditions.

MS HB252

Pharmacists; authorize to test for and administer treatment for minor, nonchronic health conditions.

MS HB1317

Pharmacists; authorize to test for and administer treatment for minor, nonchronic health conditions.

LA SB329

Provides relative to statewide protocols for pharmacists. (8/1/22)

IA HF555

A bill for an act relating to the practice of pharmacy, and providing for administrative penalties. (Formerly HSB 202.) Effective date: 07/01/2024.

IN HB1571

Pharmacists.

IN SB0145

Pharmacy matters.